NEW YORK (GenomeWeb News) – Mayo Clinic has acquired a non-exclusive license to Expression Pathology's patent for use in diagnosing systemic amyloidosis in formalin-fixed tissue.
Expression Pathology said today that Mayo Clinic will use the Liquid Tissue patent in a test using mass spectrometric analysis of formalin-fixed paraffin-embedded tissue. Mayo Clinic will offer the test worldwide through its Mayo Medical Laboratories reference laboratory.
The company said that its Liquid Tissue-based method helps physicians make treatment decisions for amyloidosis, which can be localized or systemic, and which can impair organs and cause cardiac or renal failure.
"Detailed mass spectrometry analysis of proteins related to specific disease conditions in FFPE tissue is opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions," Expression Pathology President and CEO Casey Eitner said today.
Financial terms of the agreement were not released.